The long noncoding RNA HOXA11 antisense induces tumor progression and stemness maintenance in cervical cancer

Hee Jung Kim, Kyung Jin Eoh, Lee Kyung Kim, Eun Ji Nam, Sun Och Yoon, Kun Hong Kim, Jae Kwan Lee, Sang Wun Kim, Young Tae Kim

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Recent research has focused on the impact of long noncoding RNA (lncRNA) in cervical carcinogenesis. However, whether HOXA11 antisense (HOXA11-AS) is involved in cervical cancer remains to be elucidated. In the present study, we examined HOXA11-AS expression levels in cervical cancer patients and determined the relationships between HOXA11-AS expression and clinicopathological factors. We also investigated the bio-functional consequences of HOXA11-AS overexpression both in vitro and in vivo. HOXA11-AS expression was significantly greater in tissues from patients with cervical cancer than in control patients (P < 0.001). Multivariate analysis showed that high HOXA11-AS was an independent prognosticator of overall survival (Hazard ratio=2.450, P=0.032). HOXA11-AS overexpression enhanced cell proliferation, migration, and tumor invasion in vitro, whereas HOXA11-AS knockdown inhibited these biologic aggressive features. These adverse changes were accompanied by characteristics of epithelial-mesenchymal transition (EMT). In vivo xenograft experiments using the siHOXA11-AS-transfected HeLa cells revealed that HOXA11-AS strongly induced tumor growth. Furthermore, we found that HOXA11-AS knockdown decreased cancer stemness and triggered the EMT program. In conclusion, HOXA11-AS overexpression correlated with poor survival in patients with cervical cancer. Thus, HOXA11-AS may be a pivotal target for exploring novel cervical cancer therapeutics.

Original languageEnglish
Pages (from-to)83001-83016
Number of pages16
JournalOncotarget
Volume7
Issue number50
DOIs
Publication statusPublished - 2016 Jan 1

Fingerprint

Long Noncoding RNA
Uterine Cervical Neoplasms
Maintenance
Epithelial-Mesenchymal Transition
Neoplasms
Survival
HeLa Cells
Heterografts
Cell Movement
Carcinogenesis
Multivariate Analysis
Cell Proliferation
Growth
Research

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Kim, Hee Jung ; Eoh, Kyung Jin ; Kim, Lee Kyung ; Nam, Eun Ji ; Yoon, Sun Och ; Kim, Kun Hong ; Lee, Jae Kwan ; Kim, Sang Wun ; Kim, Young Tae. / The long noncoding RNA HOXA11 antisense induces tumor progression and stemness maintenance in cervical cancer. In: Oncotarget. 2016 ; Vol. 7, No. 50. pp. 83001-83016.
@article{9183720577d44508879a096bfd347da1,
title = "The long noncoding RNA HOXA11 antisense induces tumor progression and stemness maintenance in cervical cancer",
abstract = "Recent research has focused on the impact of long noncoding RNA (lncRNA) in cervical carcinogenesis. However, whether HOXA11 antisense (HOXA11-AS) is involved in cervical cancer remains to be elucidated. In the present study, we examined HOXA11-AS expression levels in cervical cancer patients and determined the relationships between HOXA11-AS expression and clinicopathological factors. We also investigated the bio-functional consequences of HOXA11-AS overexpression both in vitro and in vivo. HOXA11-AS expression was significantly greater in tissues from patients with cervical cancer than in control patients (P < 0.001). Multivariate analysis showed that high HOXA11-AS was an independent prognosticator of overall survival (Hazard ratio=2.450, P=0.032). HOXA11-AS overexpression enhanced cell proliferation, migration, and tumor invasion in vitro, whereas HOXA11-AS knockdown inhibited these biologic aggressive features. These adverse changes were accompanied by characteristics of epithelial-mesenchymal transition (EMT). In vivo xenograft experiments using the siHOXA11-AS-transfected HeLa cells revealed that HOXA11-AS strongly induced tumor growth. Furthermore, we found that HOXA11-AS knockdown decreased cancer stemness and triggered the EMT program. In conclusion, HOXA11-AS overexpression correlated with poor survival in patients with cervical cancer. Thus, HOXA11-AS may be a pivotal target for exploring novel cervical cancer therapeutics.",
author = "Kim, {Hee Jung} and Eoh, {Kyung Jin} and Kim, {Lee Kyung} and Nam, {Eun Ji} and Yoon, {Sun Och} and Kim, {Kun Hong} and Lee, {Jae Kwan} and Kim, {Sang Wun} and Kim, {Young Tae}",
year = "2016",
month = "1",
day = "1",
doi = "10.18632/oncotarget.12863",
language = "English",
volume = "7",
pages = "83001--83016",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "50",

}

The long noncoding RNA HOXA11 antisense induces tumor progression and stemness maintenance in cervical cancer. / Kim, Hee Jung; Eoh, Kyung Jin; Kim, Lee Kyung; Nam, Eun Ji; Yoon, Sun Och; Kim, Kun Hong; Lee, Jae Kwan; Kim, Sang Wun; Kim, Young Tae.

In: Oncotarget, Vol. 7, No. 50, 01.01.2016, p. 83001-83016.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The long noncoding RNA HOXA11 antisense induces tumor progression and stemness maintenance in cervical cancer

AU - Kim, Hee Jung

AU - Eoh, Kyung Jin

AU - Kim, Lee Kyung

AU - Nam, Eun Ji

AU - Yoon, Sun Och

AU - Kim, Kun Hong

AU - Lee, Jae Kwan

AU - Kim, Sang Wun

AU - Kim, Young Tae

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Recent research has focused on the impact of long noncoding RNA (lncRNA) in cervical carcinogenesis. However, whether HOXA11 antisense (HOXA11-AS) is involved in cervical cancer remains to be elucidated. In the present study, we examined HOXA11-AS expression levels in cervical cancer patients and determined the relationships between HOXA11-AS expression and clinicopathological factors. We also investigated the bio-functional consequences of HOXA11-AS overexpression both in vitro and in vivo. HOXA11-AS expression was significantly greater in tissues from patients with cervical cancer than in control patients (P < 0.001). Multivariate analysis showed that high HOXA11-AS was an independent prognosticator of overall survival (Hazard ratio=2.450, P=0.032). HOXA11-AS overexpression enhanced cell proliferation, migration, and tumor invasion in vitro, whereas HOXA11-AS knockdown inhibited these biologic aggressive features. These adverse changes were accompanied by characteristics of epithelial-mesenchymal transition (EMT). In vivo xenograft experiments using the siHOXA11-AS-transfected HeLa cells revealed that HOXA11-AS strongly induced tumor growth. Furthermore, we found that HOXA11-AS knockdown decreased cancer stemness and triggered the EMT program. In conclusion, HOXA11-AS overexpression correlated with poor survival in patients with cervical cancer. Thus, HOXA11-AS may be a pivotal target for exploring novel cervical cancer therapeutics.

AB - Recent research has focused on the impact of long noncoding RNA (lncRNA) in cervical carcinogenesis. However, whether HOXA11 antisense (HOXA11-AS) is involved in cervical cancer remains to be elucidated. In the present study, we examined HOXA11-AS expression levels in cervical cancer patients and determined the relationships between HOXA11-AS expression and clinicopathological factors. We also investigated the bio-functional consequences of HOXA11-AS overexpression both in vitro and in vivo. HOXA11-AS expression was significantly greater in tissues from patients with cervical cancer than in control patients (P < 0.001). Multivariate analysis showed that high HOXA11-AS was an independent prognosticator of overall survival (Hazard ratio=2.450, P=0.032). HOXA11-AS overexpression enhanced cell proliferation, migration, and tumor invasion in vitro, whereas HOXA11-AS knockdown inhibited these biologic aggressive features. These adverse changes were accompanied by characteristics of epithelial-mesenchymal transition (EMT). In vivo xenograft experiments using the siHOXA11-AS-transfected HeLa cells revealed that HOXA11-AS strongly induced tumor growth. Furthermore, we found that HOXA11-AS knockdown decreased cancer stemness and triggered the EMT program. In conclusion, HOXA11-AS overexpression correlated with poor survival in patients with cervical cancer. Thus, HOXA11-AS may be a pivotal target for exploring novel cervical cancer therapeutics.

UR - http://www.scopus.com/inward/record.url?scp=85003956480&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85003956480&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.12863

DO - 10.18632/oncotarget.12863

M3 - Article

C2 - 27792998

AN - SCOPUS:85003956480

VL - 7

SP - 83001

EP - 83016

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 50

ER -